Published in Circulation on December 01, 1990
Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.41
Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol (2007) 1.32
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart (2004) 0.98
Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res (2015) 0.96
Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart (1997) 0.95
Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J (1994) 0.85
Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. Heart (1996) 0.85
Exercise induced vasodepressor syncope. Br Heart J (1994) 0.84
The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int (2011) 0.84
Heart rate recovery in patients with hypertrophic cardiomyopathy. Am J Cardiol (2013) 0.79
Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations. Heart Rhythm (2009) 0.78
Effects of lifestyle changes and high-dose β-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy. Cardiol Young (2014) 0.78
Forearm vascular responses during semierect dynamic leg exercise in patients following myocardial infarction. Heart Vessels (1998) 0.77
Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers. Br J Clin Pharmacol (2013) 0.76
Forearm vasoconstriction during dynamic leg exercise in patients with chronic heart failure. Heart Vessels (1998) 0.76
Hemodynamic stress in hypertrophic cardiomyopathy, blood pressure changes: the age factor/the law of Laplace. Circulation (1991) 0.75
Apical hypertrophic cardiomyopathy: a case of slow flow in lad and malign ventricular arrhythmia. Int J Cardiovasc Imaging (2005) 0.75
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 2.26
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart (2004) 2.22
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol (1998) 2.03
Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart (2007) 1.97
Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J (1981) 1.91
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol (1990) 1.91
High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation (2009) 1.83
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation (1999) 1.76
Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol (2001) 1.74
M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol (1980) 1.72
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart (2000) 1.66
Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol (1992) 1.66
Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation (2001) 1.64
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.60
Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology (2008) 1.57
Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 1.57
Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation (1997) 1.48
Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J (1981) 1.46
Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol (1990) 1.45
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation (1999) 1.44
Ventricular tachycardia of left bundle branch block configuration in patients with isolated right ventricular dilatation. Clinical and electrophysiological features. Br Heart J (1984) 1.42
Reflex responses of venous capacitance vessels in patients with hypertrophic cardiomyopathy. Clin Sci (Lond) (1998) 1.41
Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J (1988) 1.41
Side effects and possible contraindications of amiodarone use. Am Heart J (1983) 1.40
Human chagasic disease is not associated with an antiheart humoral response. Am J Cardiol (1997) 1.40
Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J (1996) 1.39
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation (1992) 1.38
Familial dilated cardiomyopathy in the United Kingdom. Br Heart J (1995) 1.37
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J (1999) 1.36
Amiodarone therapy during pregnancy. Am J Cardiol (1983) 1.35
Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol (1997) 1.32
Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation (1998) 1.31
Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol (1980) 1.30
Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child (1984) 1.29
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J (1999) 1.29
Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys J (2009) 1.28
Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol (2000) 1.28
Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol (2000) 1.27
Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol (1984) 1.26
A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation (2000) 1.26
Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart (2005) 1.24
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. J Am Coll Cardiol (1995) 1.24
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.18
Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation (1997) 1.18
A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. Lancet (2001) 1.17
Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation (1995) 1.17
Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart (2008) 1.17
Myocardial infarction with normal coronary angiogram. Possible mechanism of smoking risk in coronary artery disease. Br Heart J (1980) 1.16
Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol (1996) 1.15
Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart (2005) 1.15
Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J (1991) 1.15
A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12. Am J Hum Genet (1990) 1.14
A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart (1999) 1.14
Heart rate variability in idiopathic dilated cardiomyopathy: relation to disease severity and prognosis. Heart (1997) 1.12
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation (1999) 1.11
Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1999) 1.11
The plasma release of atrial natriuretic peptide in man. Clin Sci (Lond) (1986) 1.11
Hypertrophic cardiomyopathy--pathology and pathogenesis. Histopathology (1995) 1.10
Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br Heart J (1989) 1.10
Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognostic features. Circulation (1993) 1.10
Assessment of right ventricular function and anatomy using peripheral vein infusion of krypton 81m. Br J Radiol (1983) 1.08
Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart (2000) 1.08
Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart (1997) 1.07
The natural history of left ventricular hypertrophy in hypertrophic cardiomyopathy: an electrocardiographic study. Circulation (1982) 1.06
Task Force on Sudden Cardiac Death, European Society of Cardiology. Europace (2002) 1.05
Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet (1994) 1.05